VOL. XLI NO. 3 THE JOURNAL OF ANTIBIOTICS 379 were commercially obtained from the manufactures as follows : Cefazolin, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan; cefmetazole, Sankyo Co., Ltd., Tokyo, Japan; cephaloridine, cefamandole, Shionogi & Co., Ltd., Osaka, Japan; cefsulodin, Takeda Chemical Industries, Ltd., Osaka, Japan; cefotaxime, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan; cefoperazone, Toyama Chemical Co., Ltd., Toyama, Japan; ceftazidime, Glaxo Inc., London, England.
Bacterial Strains
Standard strains of bacteria were obtained from Institute for Fermentation, Osaka, Japan. A total of 279 bacterial isolates including /3-lactamase producing resistant strains of P. aeruginosa were recent clinical isolates collected from several hospitals in Japan.
Determination of MIC MICvalues were determined by the 2-fold agar dilution method with Mueller-Hinton medium (Difco Laboratories, Detroit, U.S.A.). Bacteria were cultured overnight at 37°C, and diluted to a final inoculum of 106 cfu/ml with Mueller-Hinton broth (MHB, Difco Laboratories, Detroit, U.S.A.). 5 iA of the diluted broth culture was inoculated onto the agar plates containing antibiotics with a Microplanter (Sakuma Seisakusho, Ltd., Tokyo, Japan) to give a final inoculum of 5 x 103 cfu and bacterial growth was observed 18 hours after the inoculation at 37°C. The MICwas defined as the lowest antibiotic concentration which prevented visible bacterial growth.
Determination of MBC
MBCvalues were determined with 18-hour broth cultures of bacteria in MHB. Bacteria were cultured overnight at 37°C, and diluted to 2 x 104 cfu/ml with MHB.Test tubes containing 1 ml of the culture dilutions and 1 ml of serial 2-fold dilutions of antibiotics were incubated at 37°C for 18 hours. After incubation, the broth dilution MIC was determined as the lowest antibiotic concentration inhibiting visible bacterial growth. 5 jul from each tube inhibiting visible bacterial growth was inoculated on agar plates with a Microplanter. After 18 hours of incubation at 37°C, MBCwas determined as the lowest antibiotic concentration which prevented bacterial growth on the agar plate.
-Lactamases /3-Lactamases obtained from P. aeruginosa 3R, 12R and 16R were prepared according to the method of Minamiet al.6\ Bacteria were cultured at a concentration of 5 xl08 cfu/ml in MHBat 37°C for 4 hours, and collected by centrifugation at 7,500 x g for 10 minutes. Then, the bacteria were sonicated and centrifuged at 13,000 x g for 30 minutes. The resulting supernatant was used as a crude enzyme solution. /3-Lactamase obtained from Enterobacter cloacae was purchased from Sigma Chemical Company, St. Louis, U.S.A. /5-Lactamases obtained from Citrobacter freundii GN 7391 and Proteus vulgaris 1427 were kindly provided from Dr. M. Tajima.
Assay of /3-Lactamase /3-Lactamase assay was carried out by the spectrophotometric method of Ross and O'Callaghan70. The decrease in absorbance of the substrate at an appropriate wavelength was measured in a tempera- MAR. 1988 54 mCi/mmol, Amersham International pic, England) was added and incubated for further 10 minutes at 30°C. The binding was terminated by the addition of 2 /A of 15 % (w/v) Sarkosyl solution containing 45 mg unlabeled benzylpenicillin per ml (Banyu Pharmaceutical Co., Ltd., Tokyo, Japan). After the suspension was allowed to stand for 20 minutes at 20°C, the inner membranefraction (Sarkosylsoluble fraction) was obtained by centrifugation at 14,000 xg for 30 minutes at 20°C. The fraction was mixed with 15 [A of 0.2 m Tris-HCl buffer (pH 6.8) containing sodium dodecyl sulfate 3 % (w/v), glycerol 30% (w/v), bromophenol blue 0.002% (w/v), and 4.5 {A of 2-mercaptoethanol, and heated in a boiling water bath for 2 minutes. 10 [A of the solution was then subjected to slab gel electrophoresis according to the method of Noguchi et al.Q\ After electrophoresis, the gel was fixed in 300 ml of 30%methanol-10% acetic acid for 15 hours at room temp, and washed 5 times for 0.5~1 hour each with 300ml of the same solution. The gel was soaked in 300ml of Enlightning (New England Nuclear, U.S.A.) with gentle shaking for 45 minutes, and dried in vacuo on WhatmanNo. 3 MMpaper. A fluorogram was prepared by exposing the gel to X-ray film (Kodak X-Omat AR film) at -80°C for 3-4 weeks. The concentrations of antibiotics required for 50%binding inhibition of 14C-labeled benzylpenicillin to PBPs (IC50s) were determined with a Densitometer (Model CS-900; Shimadzu Corp., Kyoto, Japan) from the fluorograms.
Determination of In Vivo Activity
In vivo antibacterial activities of antibiotics were studied in 4-week-old male ICR strain mice (Shizuoka Laboratory Animal Center, Shizuoka, Japan). Ten mice per group were intraperitoneally infected with 2 to 8 times the 50%lethal doses of the bacteria suspended in 0.2 ml of sterile saline containing 5% gastric mucin (Nakarai Chemicals, Ltd., Tokyo, Japan). Challenge doses ranged from 7 x 104 to 3 x 108 cfu per mouse. Appropriate doses of antibiotics were administered intravenously 1 hour after infection. The 50%effective dose (ED50) was calculated by the Litchfield-Wilcoxon method10) from the number of mice surviving 7 days after infection.
Serum Protein Binding
One volume of an antibiotic solution (1,000^g/ml) in 1/15 m phosphate buffer solution (pH 7.0) was added to 9 volumes of fresh sera of mice, rats and humans. The reaction mixture was incubated at 37°C for 1 hour with gentle shaking and then subjected to centrifugal ultrafiltration with a MPS-3 device (Amicon Corp., Denvers, U.S.A.). The protein-free ultrafiltrate, containing the unbound antibiotic, was microbiologically assayed by using P. vulgaris GN5298 as a test organism. Plasma Concentrations of Antibiotics Antibiotics dissolved in sterile physiological saline just before use, were administered intravenously to ICR strain mice at a dose of 20 mg/kg. Blood samples of mice in groups of five were withdrawn from the heart with heparinized syringes at 1, 2.5, 5, 10, 20, 30, 40, 60, 120 and 240 minutes after administration, respectively. Plasma was separated from these heparinized blood samples by centrifuging at 1,400xg at 4°C, and 50/4 of 0.14 n hydrochloric acid was added to a portion of 100 [A of each plasma sample of M14659for HPLCanalysis. Plasma samples were stored at -80°C until analyzed. Antibiotic concentration of the plasma was determined by bioassay using P. vulgaris GN 5298 as a test organism. Plasma concentrations of M14659were also determined by HPLC.
Urinary Concentrations of Antibiotics Antibiotics dissolved in sterile physiological saline just before use, were administered intravenously to two ICR strain mice per metabolic cage at a dose of 20 mg/kg. Urine samples from five cages were collected at 0 to 3, 3 to 6, 6 to 9, and 9 to 24 hours after administration, and 400 [A of0.5 m acetate buffer (pH 4.0) was added to a portion of 100 [A of each urine sample of Ml4659 for HPLCanalysis. Urine samples were stored at -80°C until analyzed. Antibiotic concentration of the urine was determined as described above. Pharmacokinetic Analysis The two-compartment model was used for pharmacokinetic analysis of M14659, and the onecompartment model for ceftazidime. The plasma half-lives (T1/2(a) and T1/2(/3)), the total body clearance (CLtot), and the area under the plasma concentration versus time curve extrapolated to time infinity (AUC) were calculated by means of residual method and the following equations :
where Drepresents the dose, Co is the extrapolated initial plasma concentration, and k/5 is the elimination rate constant.
Results

Antibacterial
Spectrum and In Vitro Activity of M14659 M14659is a potent, broad-spectrum cephalosporin, equally active on a weight basis against S. aureus and P. aeruginosa at concentrations in the range 0.20 to 3.13^g/ml. Enterobacteriaceae were susceptible to very low concentrations of M14659; MIC90values were in the range 0.10 to 1.56^g/ml for selected and clinical isolates (Tables 1 and 2). M14659 has excellent anti-pseudomonal activity (MIC90 0.20^g/ml). The range of MICs was narrow for clinical isolates and suggests that the cephalosporin has considerable potential for use in pseudomonal infections. In comparative studies, M14659was shown to be considerably more active than cefsulodin or cefoperazone in terms of MIC90. Ceftazidime was active at comparableconcentrations against some strains but M14659had greater activity against some ceftazidime-resistant isolates. This property was further demonstrated for three /3-lactamase producing P. aeruginosa strains (Table 3 ).
M14659 retained its activity, whereas cefsulodin, cefoperazone, cefotaxime and ceftazidime were inactive against these isolates. M14659 has good activity against S. aureus and Staphylococcus epidermidis; MIC90 6.25^g/ml for clinical isolates. This is less active on a weight basis than cefamandole but M14659is more active in vitro than ceftazidime. All of the cephalosporins were inactive against methicillin-resistant strains. The in vitro activity of M14659 against Enterobacteriaceae is typical of aminothiazolyl cephalosporins and in comparative studies, M14659was shownto be as effective as cefotaxime or ceftazidime. Against Enterobacter strains, M14659was effective against 46 isolates over a narrow concentration range, 0.02 to 1.56 /^g/ml. Both cefotaxime and ceftazidime were inactive to some of these isolates Staphylococcus aureus (14) MRSAb (15) Escherichia coli (63) Klebsiella sp. (50) Serratia sp. (10) Enterobacter sp. (46) Citrobacter sp. (10) Indole-positive Proteus sp. (6) Indole-negative Proteus sp. (1 5) Pseudomonas aeruginosa (50) at concentrations up to 100^g/ml. This finding suggests that Ml4659 may have potential for use against Enterobacter strains which are currently resistant to other cephalosporins. Ml4659 is bactericidal at concentrations close to the MIC (Table 4) . MBCsof both ceftazidime and M14659 were similar for three selected isolates. These preliminary findings indicate that M14659 384 THE JOURNAL OF ANTIBIOTICS MICwas determined by broth dilution method.
Inoculum size : 104 cfu/ml. Enterobacter cloacae, C.f. ; Citrobacterfreundii, P.v. ; Proteus vulgaris, P.a. ; Pseudomonas aeruginosa. a Rates of hydrolysis of antibiotics are expressed in percent hydrolysis of cephaloridine. b Ki values were determined by using nitrocefin as a substrate. NT: Not tested.
should be effective as a bactericidal agent.
Kinetics of Hydrolysis
Ml4659 was very stable to /J-lactamases from P. vulgaris, E. cloacae, C. freundii and P. aeruginosa (Table 5) ; ceftazidime showed similar stability in terms of relative hydrolysis rates (Vmax) compared with the labile compoundscephaloridine and nitrocefin. M14659was more stable than cefotaxime in the presence of^-lactamase from P. vulgaris. M14659showed similar affinity to ceftazidime for enzymes from E. cloacae and C. freundii. Ki values 6.8^m and 0.24^m respectively compared with 5.6^m and 0.37 fiM for ceftazidime. In the presence of Pseudomonas jS-lactamases, M14659 showed 2 to 4-fold lower affinity compared with ceftazidime and at least 100 times lower affinity than cefotaxime.
Inhibition
of PBPs Affinities of M14659 and ceftazidime for PBPs are shown in Table 6 . M14659 like ceftazidime inhibits PBP-3 preferentially at a similar IC50, approximately 0.2^g/ml, in E. coli. M14659 inhibited PBPs 1A and IB of E. coli at lower concentrations than ceftazidime, 0.3 and 0.7 //g/ml, respectively. Additionally M14659 acts at 12 /ug/ml against PBP-2. This property may be of advantage as this PBP is an essential protein like PBP-3 in E. coli. Similarly in P. aeruginosa M14659 inhibited PBPs 1A and IB at lower IC50s than ceftazidime, 0.08 and 6.0^g/ml, respectively, and PBPs 3 and 4 at similar IC50s to ceftazidime, 0.08 and 1.0^g/ml, respectively. In Vivo Activity of M14659 Ml4659 was effective in treating experimental septicaemia in mice following challenge with a range of Gram-positive and Gram-negative organisms (Table 7) . S. aureus infections responded well, ED50values for Ml4659 were comparable with those for cefazolin, and lower than those of cefotaxime The number in parentheses is a molar ratio to 14C-labeled benzylpenicillin required for 50 % inhibition binding of labeled benzylpenicillin. 8  0  2  1  0  0  0  0  42  1  3  71  26  2  78  42  69  240   218  45  238  51  178  32  170  64  244   83  63  73  60  91  14  35  59  65   16  00  97  10  77  04  04   94  09  26  73  13  91  83  19  4  73 a Mice were infected intraperitoneally with 0.2 ml of a bacterial suspension in saline containing 5 %gastric Results are given as means±SEfor 5 mice. ND : Not detected.
a Plasma half-life at a phase. b Plasma half-life at /3 phase. and ceftazidime. Some response to Ml4659 was also seen in infections due to methicillin-resistant Staphylococci (MRSA), though its MICs were relatively high; ED50 values of Ml4659 ranged from 1.44 to 9.79 mg/kg, and were lower than those of cefazolin, cefmetazole, cefamandole, cefotaxime or ceftazidime. Even in the infection due to MRSA4-2, which has been isolated from MRSA4 as a single colony by using an agar plate containing 25 jug of cefazolin per ml after the culture at 44°C for 8 hours to eliminate penicillinase-encoding plasmids and induces PBP-2', Ml4659 was more active than the comparative compounds. Therefore, the activity of M14659to the MRSA infections seemed to be attributable not to the heterogenicity of the isolates but to its activity in vivo.
Pseudomonas infections responded at ED5Osin the range 32 to 69.5 mg/kg M14659; ceftazidime was 3 to 5-fold less active than M14659.
Ml4659was as effective as ceftazidime in protection tests using E. coli and Proteus species, and more active than ceftazidime against Klebsiella pneumoniaeand Serratia marcescens. TwoEnterobacter infections were moresusceptible to Ml4659than to cefotaxime or ceftazidime. This finding correlates with the low affinity of Ml4659 for Enterobacter /3-lactamase and the narrow MICrange observed for clinical isolates. Citrobacter strains which produce a similar chromosomal/3-lactamase were also effectively eradicated in experimental infections. Results are given as means±SE for 10 mice. ND: Not detected.
Serum Protein Binding of M14659 The percentages of binding of M14659to human, mouse and rat serum were 90.8, 63.0 and 95.4%, respectively. Corresponding values for ceftazidime to the respective sera were 25.5, 4.2 and 12.0%, respectively. Thus, M14659 was highly bound to the serum proteins of humans, mice and rats as compared with ceftazidime (Table 8 ).
Plasma Concentrations of Ml4659
After intravenous administration plasma concentrations of M14659in mice were markedly higher than those of ceftazidime (Table 9) , and M14659was still detected at a concentration of 1.3^g/ml by bioassay and 2.0^g/ml by HPLCin mouse plasma 120 minutes after administration, when ceftazidime was not detected. Further, the plasma half-lives of M14659were 0.6 minute at a phase and 26.3 minutes at fi phase by bioassay, and 3.0 and 29.6 minutes by HPLC, respectively. AUCand CLtot of M14659 were 1,386 jug -minutes/ml and 14.4 ml/minute/kg by bioassay, and 1,725 jug -minutes/ ml and ll.6 ml/minute/kg by HPLC, respectively. An a phase was not observed with ceftazidime, and the plasma half-life at /3 phase was 10.6 minutes by bioassay. AUCand CLtot of ceftazidime were 569^g-minutes/ml and 35.1 ml/minute/kg by bioassay (Table 9 ).
Urinary Concentrations of Ml4659 Recovery of M14659in mouse urine collected at 0 to 24 hours after administration was 67.8% by bioassay, and 67.0% by HPLC. The recovery of ceftazidime was 74.2% by bioassay (Table 10) .
Discussion
A number of anti-pseudomonal cephalosporins like ceftazidime has been developed as alternative treatments for serious pseudomonal infections which have been traditionally treated with aminoglycosides alone or in combination with /3-lactam antibiotics. Although ceftazidime is reported to be the most potent anti-pseudomonal agent among currently clinically used cephalosporinsi:>, it is also true that its anti-staphylococcal activity is poor0. Further, some clinical isolates ofP. aeruginosa resistant to ceftazidime have already been reported3»4). Our search for a new cephalosporin with a balanced spectrum of activity and more potent anti-pseudomonal activity than ceftazidime has resulted in the development of Ml4659.
Ml4659 has a broad antibacterial spectrum covering Gram-positive and Gram-negative bacteria, similar to that exhibited by cefotaxime and ceftazidime. M14659was more active in vitro than ceftazidime against clinical isolates of S. aureus including methicillin-resistant strains, and equipotent to ceftazidime against Gram-negative isolates excepting P. aeruginosa. Against clinical isolates of P. aeruginosa, Ml4659was superior to anti-pseudomonal cephalosporins such as cefsulodin, cefoper-389 azone and ceftazidime. Generally, Pseudomonasspecies are knownto be resistant to /3-lactam antibiotics via three possible mechanisms4) : (1) Production of chromosomal or plasmid mediated^-lactamases, (2) altered permeability to /3-lactam antibiotics, or (3) altered penicillin-binding proteins. Mechanism (3), however, is thought to be infrequent4). Our study using /3-lactamase producing strains of P. aeruginosa, which are thought to be resistant to cefsulodin, cefoperazone and ceftazidime mainly via mechanism (1) or both (1) and (2), indicated that M14659 was also active against resistant strains of P. aeruginosa, and Ml4659was very stable to the /3-lactamases obtained from the strains. Further, the affinities of M14659for the /3-lactamases, which were expressed as Ki values, were lower than those of cefotaxime and ceftazidime. Recently, it has been proposed that the tight binding of non-hydrolyzable cephems by periplasmic^-lactamase molecules, i.e., trapping, could prevent them from binding to target PBPs and create the resistance seen in certain strains of bacteria such as Entervbacter, Serratia, and Pseudomonasn>12\ If this theory is true, the excellent activity of M14659 against the /3-lactamase producing resistant strains of P. aeruginosa may be attributable to its low affinity for their chromosomal^-lactamase. Furthermore, Ml4659 showed greater affinity than ceftazidime for PBP-1A and PBP-1B of E. coli and P. aeruginosa. Both these factors may be important in the bactericidal activity of Ml4659and its activity against P. aeruginosa which are resistant to other so-called thirdgenerationcephalosporins.
In vivo activity of Ml4659 against experimental systemic infections due to S. aureus including methicillin-resistant strains was superior to that of cefotaxime or ceftazidime. Against infections due to Gram-negative bacteria except P. aeruginosa, M14659 was 3. to 220 times more active than cefotaxime and 2 to 20 times than ceftazidime on the basis of ED50values, though MICs of M14659 against the challenge strains were similar to or higher than those of cefotaxime and ceftazidime. Furthermore, its in vivo activity against P. aeruginosa was marginally superior to that of ceftazidime, probably mainly reflecting the higher in vitro activity of the compound. Against the other test organisms Ml4659 showed a more potent therapeutic effect than might be expected in comparison of its MICswith those of ceftazidime. This might be explained by more advantageous pharmacokinetic properties of the former compound. M14659 was found more highly bound to human, mouse and rat serum proteins than ceftazidime. Plasma half-life of Ml4659 in mice was, however, much longer than that of ceftazidime, and Ml4659 at a concentration thought to inhibit many Gram-negative bacteria was still detected in mouse plasma 120 minutes after an intravenous dose of 20 mg/kg of the compound, similar to what has been reported for ceftriaxone13). However, the urinary excretion of Ml4659in mice was as high as that of ceftazidime. These results suggest that Ml4659is a long-acting compoundsimilar to ceftriaxone, and these characteristics maycontribute to the excellent therapeutic properties of M14659. However, since several /3-lactam antibiotics have been reported to show strong in vivo activities because of their (i) synergism with serum factors14), (ii) facilitation of phagocytosis of neutrophils through antibiotic action on bacteria15>16), or (iii) activation of phagocyte functions17), further studies on participation of these factors maybe required to explain the good therapeutic effect of M14659 more fully.
In conclusion, these findings indicate that Ml4659 is a novel anti-pseudomonal cephalosporin which has a balanced spectrum of activity and promising therapeutic activity in experimental infections in mice. If preliminary findings are borne out in man, Ml4659 has considerable potential for the treatment of a wide range of infections and may be a valuable alternative to currently available anti-pseudomonal cephalosporins.
Experimental
NMRspectra were determined with a Jeol FX-90Qspectrometer. IR spectra were recorded on a Nicolet 5DXspectrometer. Optical rotation was measured with a Jasco DIP-181 polarimeter.
Thionyl chloride (60 ml) was added to a suspension of (3,4-diacetoxyphenyl)acetic acid (51.1 g) in 105 ml of CC14, and the mixture was heated at 70°C for 1 hour. After cooling to room temp, N-390 THE JOURNAL OF ANTIBIOTICS MAR. 1988 bromosuccinimide (42.3 g), CC14 (105 ml) and a little amount of HBr were added, and the mixture was heated for an additional 1 hour. The resulting mixture was concentrated under reduced pressure, and the residue was redissolved in CC14. After filtering off insoluble material, the filtrate was dissolved in 400ml of Me2COand the pH of the soln was adjusted to 4.0 with satd NaHCO3aq soln under ice-cooling. The resulting mixture was extracted with CHC13.The CHC13layer was washed with satd NaCl aq soln and dried over anhydrous Na2SO4. The dried soln was concentrated under reduced pressure to give 61.4 g of 2-bromo-2-(3,4-diacetoxyphenyl)acetic acid (I). Then, diphenyldiazomethane (39.6 g) was added to a soln of the product I (61.4 g) in 500 ml of Me2CO,and the soln was stirred at room temp for 1 hour. The resulting soln was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give 48.4 g of diphenylmethyl 2-bromo-2-(3,4-diacetoxyphenyl)acetate (II). The product II (48.4 g) in 200 ml of MeCN and Et3N (13.6 ml) were added to an ice-cooled suspension of iV-hydroxyphthalimide (15.9 g) in 300 ml of MeCN.The mixture was stirred under ice-cooling for 1.5 hours. The resulting soln was concentrated under reduced pressure and redissolved in EtOAc. The soln was washed with H2O, 1 n citric acid soln and with satd NaCl aq soln in that order. The washed soln was dried over anhydrous Na2SO4and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 15.3 g of diphenylmethyl 2-phthalimidooxy-2-(3,4-diacetoxyphenyl)acetate (III). To a soln of the product III (15.3 g) in 200 ml of CH2C12, methylhydrazine (1.34 ml) was slowly added at -60°C, and the mixture was allowed to stand until room temp was reached. After stirring for 2 hours, methylhydrazine (0.07 ml) was added to the mixture, followed by stirring for an additional 30 minutes. The insoluble material was filtered off, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 8.7 g of diphenylmethyl 2-aminooxy-(3,4-diacetoxyphenyl)acetate (IV). A soln of the product IV (8.7 g) in 150 ml of MeOHwas added dropwise to a soln of (2-triphenylmethylamino-4-thiazolyl)glyoxylic acid (7.62 g) in 400 ml of MeOH.The mixture was stirred at roomtemp for 1.5 hours, and concentrated under reduced pressure to give (5.0 g) in 170 ml of CH2C12, 1.4 g of dicyclohexylcarbodiimide was added, and the mixture was stirred at room temp for 5 hours. After filtering off the insoluble material, the filtrate was concentrated under reduced pressure. The residue was dissolved in EtOAc and the material was filtered off. The filtrate was washed with satd NaCl aq soln and dried over anhydrous Na2SO4.The dried soln was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 0.73 g of the objective compound 2: IR (KBr) To a soln of the compound 2 (0.73 g) in 3 ml of C1CH2CH2C1, anisole (0.4 ml) and CF3COOH (0.8 ml) were added under ice-cooling, and the resulting soln was stirred at room temp for 3 hours. Additional CF3COOH (0.6 ml) was added and the mixture was stirred for another 30 minutes. After removing the solvent by decantation, the residue was washed with C1CH2CH2C1and crystallized with Et2O to give 0.3 g of the product V. The product V (0.27 g) was suspended in ll ml ofH2O, and the pH of the mixture was adjusted to 8.0 with NaHC03. After stirring at room temp for 6 hours, the resulting soln was applied to a Diaion HP-10 column. The appropriate fractions eluted with H2O were collected and lyophilized to give 0.14 g of M14659: IR (KBr) 
